Carcinogenesis Advance Access published online on June 10, 2008
Carcinogenesis, doi:10.1093/carcin/bgn139
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Suppressive function of RKTG on chemical carcinogen-induced skin carcinogenesis in mouse
Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Graduate School of the Chinese Academy of Sciences, Shanghai 200031, China
* Corresponding Author: Yan Chen, M.D., Ph.D., Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Rd., Shanghai 200031, China Email: ychen3{at}sibs.ac.cn Tel: 86-21-54920916, Fax: 86-21-54920291
RKTG (Raf Kinase Trapping to Golgi) is a newly characterized negative regulator of the Ras-Raf-MEK-ERK signaling pathway via sequestrating Raf-1 to the Golgi apparatus. However, little is known about the physiological functions of RKTG in mitogenic pathway and carcinogenesis. Here we describe a suppressive role of RKTG in skin carcinogenesis by analyzing chemical carcinogen-induced tumorigenesis. Epidermis hyperplasia and proliferation are increased in RKTG deficient mice (RKTG-/-) after acute treatment with 7, 12-dimethylbenz anthracene (DMBA) and 12-O-tetradecanoylphorbol 13-acetate (TPA). Using a two-stage DMBA/TPA carcinogenesis protocol on mouse skin, the number and size of papillomas are increased in RKTG-/- mice, accompanied by shortened tumor latency and enhanced keratinocyte proliferation. The regression of the carcinogen-induced tumors is also prolonged in RKTG-/- mice. Consistently, the levels of Raf-1 and ERK phosphorylation in primary keratinocytes as well as skin tumors are elevated when RKTG is disrupted. Collectively, our results indicate that RKTG has a suppressive activity in chemical carcinogen-induced mitogenesis and tumor formation in mouse skin.
Key Words: RKTG skin carcinogenesis Raf Ras mouse models
Received January 17, 2008; revised April 25, 2008; accepted June 3, 2008.